Table 2.

Anti-proliferative activity against six kinds of breast cancer cells by all compounds.

Compound	IC50 (μM)
	MCF-7	BT-474	SKBR-3	MDA-MB-436	MDA-MB-231	MDA-MB-468
PMM-158	12.1 ± 0.42	15.6 ± 1.03	11.5 ± 0.74	10.1 ± 0.92	9.17 ± 0.99	10.6 ± 0.65
PMM-159	9.22 ± 0.13	10.8 ± 0.94	8.95 ± 0.69	8.49 ± 0.78	7.24 ± 0.82	8.23 ± 1.27
PMM-160	15.3 ± 0.52	18.3 ± 1.24	10.5 ± 0.88	11.8 ± 0.86	9.66 ± 1.21	12.4 ± 0.52
PMM-161	9.81 ± 0.49	11.1 ± 1.12	9.29 ± 0.66	9.55 ± 0.83	8.58 ± 0.53	8.97 ± 1.05
PMM-162	9.01 ± 0.92	9.54 ± 0.91	8.03 ± 0.83	7.28 ± 0.77	6.14 ± 1.05	6.85 ± 0.92
PMM-163	8.69 ± 0.83	9.27 ± 0.86	7.56 ± 0.72	7.09 ± 0.63	6.04 ± 0.59	7.83 ± 0.55
PMM-164	5.71 ± 0.52	7.09 ± 0.65	4.49 ± 0.58	4.41 ± 0.55	3.76 ± 1.02	3.94 ± 0.73
PMM-165	9.38 ± 0.66	9.22 ± 0.98	6.23 ± 0.73	5.97 ± 0.67	5.47 ± 1.01	6.58 ± 0.15
PMM-166	6.41 ± 0.75	6.91 ± 0.73	4.87 ± 0.58	4.66 ± 0.59	3.64 ± 0.91	4.07 ± 0.66
PMM-167	15.3 ± 0.61	13.7 ± 0.92	9.76 ± 0.95	10.6 ± 0.82	9.01 ± 0.56	12.2 ± 0.42
PMM-168	9.27 ± 1.12	10.6 ± 0.81	8.16 ± 0.71	7.87 ± 0.91	6.09 ± 1.04	8.42 ± 0.86
PMM-169	8.12 ± 0.98	8.36 ± 0.97	6.95 ± 0.82	7.36 ± 0.87	5.33 ± 0.77	7.22 ± 1.11
PMM-170	9.73 ± 1.03	12.7 ± 1.06	8.27 ± 0.69	6.88 ± 0.73	4.31 ± 0.65	8.44 ± 0.78
PMM-171	8.71 ± 0.67	8.59 ± 0.78	5.89 ± 0.64	6.49 ± 0.68	3.14 ± 1.02	6.95 ± 0.46
PMM-172	4.87 ± 0.55	5.26 ± 0.66	3.14 ± 0.46	3.07 ± 0.47	1.98 ± 0.49	3.24 ± 0.27
PMM-173	5.58 ± 0.83	6.03 ± 0.71	3.59 ± 0.49	4.06 ± 0.53	2.59 ± 0.19	3.76 ± 0.88
Shikonin	4.57 ± 0.69	5.74 ± 0.66	3.75 ± 0.52	3.28 ± 0.41	2.88 ± 0.25	3.61 ± 0.34
Stattic	5.85 ± 0.72	5.11 ± 0.57	3.39 ± 0.56	3.76 ± 0.50	3.18 ± 0.33	3.54 ± 0.42